Last reviewed · How we verify
Northera
At a glance
| Generic name | Northera |
|---|---|
| Also known as | Droxidopa |
| Sponsor | The Cooper Health System |
| Target | Muscarinic acetylcholine receptor M1, Adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Orthostatic hypotension
- Parkinson's disease
Common side effects
- Falls
- Urinary tract infections
- Headache
- Syncope
- Dizziness
- Nausea
- Hypertension
Serious adverse events
- Supine Hypertension
- Hyperpyrexia and Confusion
- Cerebrovascular accident
- Pancreatitis
- Psychosis
- Hallucination
- Chest pain
- Delirium
- Agitation
- Congestive heart failure exacerbation
Key clinical trials
- Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease. (PHASE1, PHASE2)
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure (PHASE1)
- NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome (PHASE1, PHASE2)
- Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study
- Droxidopa / Pyridostigmine in Orthostatic Hypotension (PHASE2)
- Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury (PHASE2)
- Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) (PHASE2)
- Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |